Navigation Links
Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Date:5/24/2011

29.25% between 2005 and 2010. Until the market entry of Lucentis (ranibizumab) in 2006, the RVO therapeutics market was growing at a lower rate. After the entry of Lucentis, the market registered a growth rate of 40.13% between 2006 and 2007. Up until now, Lucentis and Ozurdex have been the only approved drugs for the treatment of RVO. The late-stage clinical development pipeline consists of 50% first-in-class and 50% me-too drugs that are effective and safe for RVO patients. Once these drugs enter the market, the market will grow further at a significant rate. Therefore, GlobalData estimates that the RVO therapeutics market in 2017 will be $1.4 billion, indicating a Compound Annual Growth Rate (CAGR) of 16.08% between 2010 and 2017

Scope

The report provides information on the key drivers and challenges of the retinal vein occlusion therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) retinal vein occlusion therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as VEGF inhibitors, HMG CoA reductase inhibitors, Glucocorticoid receptor agonists, and kallikrein inhibitors.

- Analysis of the current and future competition in the seven key countries retinal vein occlusion market. Key market players covered are Allergan, Inc., Alimera Sciences, Icon Biosciences, and Regeneron Pharmaceuticals.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the retinal vein occlusion
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
2. Reportlinker Adds Triple Analysis: Lymphoma, Melanoma and Peptides
3. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
4. Reportlinker Adds Advanced Digital Medical Equipment Products Market
5. Reportlinker Adds India Medical Devices Manufacturers, Distributors and Exporters Directory 2011
6. Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
7. Reportlinker Adds Orphan Drugs in Asia 2011
8. Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry
9. Reportlinker Adds The Outlook for Medical Devices in South East Asia
10. Reportlinker Adds Pharmaceutical Management of Obesity (Technical Insights)
11. Reportlinker Adds Machine-to-Machine (M2M) Communications in Healthcare 2010-20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Officer, will present at the Stem Cell Meeting on ... 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... 2014 STUDY OBJECTIVES The objective ... provide an overview of the current and future ... The key objective is to present a comprehensive ... an important tool in the treatment of various ... strategies within the protein therapeutics market, which includes ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods ... increased 11% to $626 million. Q3 sales grew organically by ... organically by 4% and 2%, respectively.  Recently completed acquisitions contributed ... contributed an additional 5% to reported sales growth in Q3. ...
... Oct. 25, 2011 Abbott (NYSE: ABT ... – one undergraduate and one graduate – living with ... Undergraduate Student Scholarship, and Emily Kramer-Golinkoff, winner of the ... with CF who were eligible to receive the two ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees 2Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees 3
(Date:10/1/2014)... and Physical Sciences Research Council (EPSRC) will focus ... control systems which run, for example, manufacturing plants, ... network. , The research will help understand ... the systems behind our critical national infrastructure. ... Systems (RITICS), based at Imperial College London, is ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater ... of choice, is announcing a discounted cost on Botox ... , “We’re doing this because we want to give ... skin clinic in Toronto,” says Dr. Brian Sieber, founder ... Anti Aging Clinic, including laser facials, genesis laser facials, ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... diets are of no use in losing weights and are ... from the American Dietetic Association//. Dieticians consulted by WebMD also ... gym is no answer either. ,The growing rate of ... who are particularly alarmed at the increasing childhood obesity. Cynthia ...
... a Cesarean operation to deliver Japan's male heir. The ... doctor of the Imperial Household agency//. ,he ... the placenta, a condition called as placenta previa. "We ... operation. It is also highly possible that the delivery ...
... pay compensation and apologise to a young woman orphaned by ... ,Beijing Chaoyang District Court ordered the local China Times ... and issue an apology on its front page for a ... of the woman and the story of her sufferings after ...
... the treatment of recurrent ovarian cancer ignoring the advice of ... in combination with carboplatin (chemotherapy) is very effective for women ... by its generic name gemcitabine and was approved after the ... the statistics of the American Cancer Society about 22,000 women ...
... be mandatory on all tobacco products soon failing which ... ,Other health warnings that could appear on ... pictorial representation of ill-effects of tobacco use and a ... headed by Anbumani Ramadoss, who has been a staunch ...
... than half of human cancers involve mutations in the ... the normal p53 protein in defending// against cancer. Similarly, ... protein occur in its DNA-binding core domain, pointing to ... to its anti-cancer activity. ,Clearly, a detailed ...
Cached Medicine News:Health News:DNA-bound p53 Tumor Suppressor Protein Structure Determined 2
... stethoscope adapter for users of "completely-in-the-canal" ... socket" type - must send eartip., ... required. , ,Westone custom products ... our worldwide network of hearing healthcare ...
... Philips Bispectral Index (BIS®) measurement uses Aspect ... depth of consciousness and sedation monitoring for ... clinical settings., ,The plug-and-play BISx Power ... an integrated clamp for quick and easy ...
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... is Fujinon's pediatric fiberoptic ... diameter allows for more ... standard 2.0mm channel provides ... passage in all circumstances. ...
Medicine Products: